News Focus
News Focus
Followers 12
Posts 1019
Boards Moderated 0
Alias Born 03/24/2013

Re: None

Friday, 11/03/2017 1:46:57 AM

Friday, November 03, 2017 1:46:57 AM

Post# of 20689
Glatiramer EU

Doesn't make sense how it is not viable for Momenta/Sandoz in EU while Mylan/Synthon and Teva are able to reap profits. For Momenta, every $ is more critical than Sandoz, if Sandoz isn't going to pursue EU, why not partner with someone else?